Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M

By /

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.

Scroll to Top